Clinical isolate of herpes simplex virus type 2 that induces a thymidine kinase with altered substrate specificity.
In vitro and in vivo studies were done on a herpes simplex virus type 2 strain recovered from a patient on acyclovir (ACV) which was ACV resistant but expressed thymidine (dThd) kinase (EC 2.7.1.21) activity. Plaque-purified clones derived from the original clinical sample were heterogeneous with respect to plaque size and drug susceptibility. The heterogeneity of this viral mixture was also evident from varied 125I-labeled 5-iodo-2'-deoxycytidine autoradiographic patterns and from varied expression of dThd kinase-associated phosphorylating activities. Four clones from this mixture were 1-beta-D-arabinofuranosylthymine (ara-T) susceptible and ACV resistant. Extracts of cells infected with these clones catalyzed the phosphorylation of ara-T but little of ACV. The virus-coded dThd kinase was purified from one of these clones to determine whether its substrate specificity was altered. The amount of virus-coded dThd phosphorylating activity with the cell extracts was estimated to be sevenfold lower with the resistant clone than with the MS strain of herpes simplex virus type 2. The dThd kinase eluted from a dThd-agarose affinity column under the same conditions with extracts from both sources and substrate saturations of both enzymes by acyclic nucleoside analog phosphate acceptors were classical hyperbolic functions. However, there were significant differences in the kinetic parameters of substrates between the two enzymes. Apparent Km (Km') values for dThd, deoxycytidine, ara-T, ACV, and the acyclic guanosine analog 9-[[2-hydroxyl-1-(hydroxymethyl)ethoxy]methyl]guaine (BW B759U) were 2- to 60-fold higher with the variant enzyme than with the enzyme from laboratory strain MS. Comparing these two enzymes, relative maximal phosphorylation rates (Vm) were eightfold lower for ACV but unchanged for BW B759U. In contrast, the relative rates for deoxycytidine and ara-T were eight- and twofold higher, respectively. The surprisingly good substrate activity with BW B759U compared with that of ACV (Vm/Km' = 0.39 versus 0.01) coincided with susceptibility of the ACV-resistant virus to BW B759U. This clinical variant retained its pathogenicity for mice and was only moderately less neurovirulent than wild-type virus. Although such mutants have the potential to induce illness less responsive to therapy, the recurrence from which the isolate was obtained was typical for this patient in severity and duration. Since this episode, the patient has been treated successfully with ACV.
Ellis
M N
MN
Department of Virology, Burroughs Wellcome Co., Research Triange Park, North Carolina 27709.
Keller
P M
PM
Fyfe
J A
JA
Martin
J L
JL
Rooney
J F
JF
Straus
S E
SE
Lehrman
S N
SN
Barry
D W
DW
D000212:Acyclovir / Q000378:metabolism / Q000494:pharmacology; D000328:Adult; D000818:Animals; D000998:Antiviral Agents / Q000378:metabolism / Q000494:pharmacology; D001087:Arabinonucleosides / Q000378:metabolism / Q000494:pharmacology; D003001:Cloning, Molecular; D004262:DNA Restriction Enzymes; D004279:DNA, Viral / Q000032:analysis; D004352:Drug Resistance, Microbial; D004790:Enzyme Induction; D005260:Female; D006561:Herpes Simplex / Q000382:microbiology; D006801:Humans; D007700:Kinetics; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D010766:Phosphorylation; D012008:Recurrence; D018139:Simplexvirus / Q000187:drug effects / Q000201:enzymology* / Q000235:genetics; D013379:Substrate Specificity; D013936:Thymidine / Q000031:analogs & derivatives / Q000378:metabolism / Q000494:pharmacology; D013937:Thymidine Kinase / Q000096:biosynthesis* / Q000378:metabolism; D014709:Vero Cells
D000998:Antiviral Agents; D001087:Arabinonucleosides; D004279:DNA, Viral; D013937:Thymidine Kinase; D004262:DNA Restriction Enzymes; C010032:thymine arabinoside; D013936:Thymidine; D000212:Acyclovir